What Is The Buzz Surrounding Endocyte Inc (NASDAQ:ECYT)?


Endocyte Inc (NASDAQ:ECYT) has nominated Dawn Svoronos for election to company’s Board of Directors at the imminent annual stockholders meeting. Mike Sherman, the CEO and President, expressed that they are thrilled to have Svoronos stand for election to join their Board of Direction. She boasts a remarkable track record of leadership and notable experience as a Board Director at numerous life science firms. Her success in international commercial leadership roles will be especially valuable as they prepare for prospective commercialization of 177Lu-PSMA-617.

The buzz

Ms. Svoronos has extensive experience of more than 30 years in the pharmaceutical market, including her role as President of Merck & Firm’s Europe/Canada region. In addition, her earlier held roles with Merck include President of company in Canada, VP of Asia Pacific and VP of Global Marketing for the Arthritis, Analgesics & Osteoporosis franchise.

Ms. Svoronos earlier was on the board of Medivation Inc., where she served as interim Chief Commercial Officer as the firm successfully commercialized Xtandi® in advanced prostate cancer. She is presently Chair of the Board for Theratechnologies, Inc. and is a member of the Board at PTC Therapeutics, Inc., AgNovos Healthcare Company and Xenon Pharmaceuticals, Inc.

After the successful repositioning of the firm through the recent in-license of international privileges to PSMA-617 and the expected commencement of a Phase III registration study, the Board’s Nominating & Corporate Governance Committee has been performing a succession planning assessment of the Board’s tenure and composition, including talks with Board members about their respective programs.

As part of that procedure, three of Endocyte’s existing directors, Ann F. Hanham, Peter D. Meldrum and Keith E. Brauer, each of whom are fellows of Class 2 of the Board and whose existing term expires at the firm’s 2018 yearly meeting of stockholders, apprised the Committee that in advancement of Board succession programs, they would not opt for re-election at the upcoming annual meeting.


Please enter your comment!
Please enter your name here